United Therapeutics Highlights Innovation and Commitment at UBS Global Healthcare Conference

United Therapeutics Showcases Commitment to Innovation at UBS Global Healthcare Conference

United Therapeutics Corporation, a leader in the biotechnology sector and a pioneering public benefit corporation, prepares to highlight its operational advancements during a fireside chat at the upcoming UBS Global Healthcare Conference. Scheduled for November 12, 2024, from 2:45 p.m. to 3:20 p.m. PST, the discussion will feature Patrick Poisson, the company’s Executive Vice President of Technical Operations. This event not only reflects the company’s dedication to transparency but also underscores its mission to address unmet medical needs through innovative pharmaceutical therapies and organ transplant technologies. The session will be available via live webcast on the United Therapeutics website, with an archived version accessible for 180 days post-event.

At the core of United Therapeutics' operations is its commitment to inspire and innovate for the benefit of patients and stakeholders alike. As the first publicly traded biotech company to adopt the public benefit corporation model, United Therapeutics champions a dual purpose: to drive scientific advancement while prioritizing social responsibility. This innovative approach positions the company uniquely in the healthcare landscape, where the balance between profitability and public good becomes increasingly important. During the conference, Poisson is expected to delve into the company's strategic initiatives aimed at enhancing the availability and efficacy of transplantable organs, a critical area of focus for the firm.

While the upcoming conference offers a platform for sharing the latest operational updates, it also serves as a reminder of the inherent uncertainties in the biotech industry. United Therapeutics acknowledges these challenges through its forward-looking statements, which highlight potential risks that could affect anticipated outcomes. The company's proactive approach in adhering to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 reinforces its commitment to responsible communication with stakeholders regarding its innovation trajectory and public benefit objectives.

In addition to its operational focus, United Therapeutics continues to engage in meaningful dialogue about the future of healthcare innovation. The firm’s dedication to developing groundbreaking therapies not only enhances patient outcomes but also fosters a collaborative environment where innovative ideas can flourish.

As United Therapeutics positions itself for continued growth and development, its emphasis on both patient-centered care and corporate responsibility remains a cornerstone of its identity. The forthcoming fireside chat at the UBS Global Healthcare Conference is a significant opportunity for the company to share its vision and progress with a broader audience in the healthcare community.